Navamedic ASA: Q3 2021 financial results
Oslo, 4 November 2021 – Navamedic ASA (OSE: NAVA) grew revenues by 12% in the third quarter of 2021 compared to the same quarter last year. The company reported revenues of NOK 63.6 million in the third quarter of 2021 with an EBITDA of NOK 3.7 million, driven by underlying growth in the portfolio and Mysimba® in particular. The company reiterates its mid-term ambition of building a NOK 500 million company through organic growth.“Our portfolio of specialty pharma and consumer health products continue to grow with particularly strong performance for the obesity medicine Mysimba, which grew